SelectQuote (SLQT) Shares Slide Further on Disappointing Earnings Amidst DOJ Scrutiny- Hagens Berman

SelectQuote (SLQT) shares fell 12% after Q1 2025 earnings missed estimates, reporting $0.03 EPS versus an expected $0.04 and $408.16 million in revenue, below the $417.01 million consensus. This decline compounds a previous 19% drop following a DOJ lawsuit alleging False Claims Act violations related to Medicare Advantage plan marketing, where SelectQuote is accused of steering beneficiaries toward plans with the highest commissions. Hagens Berman is investigating potential securities law violations related to the alleged steering tactics.

Analysis

SelectQuote Inc. (SLQT) experienced a significant 12% share price decline on May 12, 2025, following the release of its March 2025 quarterly results, which fell short of market expectations. The company reported earnings of $0.03 per share, missing the Zacks Consensus Estimate of $0.04, and posted revenues of $408.16 million, 2.12% below the consensus estimate of $417.01 million. This financial underperformance compounds the sharp investor concerns already triggered by a U.S. Department of Justice (DOJ) lawsuit announced on May 1st, which had previously caused an over 19% drop in SLQT's stock. The DOJ lawsuit accuses SelectQuote, along with other major health insurers like Aetna, Anthem, and Humana, of violating the False Claims Act in their marketing of Medicare Advantage plans from 2016 through at least 2021. Allegations include steering beneficiaries towards plans with the highest commissions irrespective of suitability, incentivizing sales based on these commissions, and potentially discriminating against beneficiaries with disabilities. Further intensifying scrutiny, law firm Hagens Berman has initiated an investigation into potential U.S. securities law violations by SelectQuote, with the firm noting that the recent earnings miss underscores concerns related to the alleged steering tactics highlighted in the DOJ's lawsuit. The combination of these legal challenges and disappointing financial results indicates substantial headwinds for SelectQuote, impacting its operational integrity and investor confidence, reflected in a strongly negative sentiment score of -0.8 for the company.

Key Decisions for Investors

• Investors should exercise extreme caution regarding SelectQuote (SLQT) due to the dual impact of missed earnings and serious allegations from the Department of Justice lawsuit, which have already led to substantial stock price declines.
• Closely monitor all developments related to the DOJ lawsuit and the Hagens Berman securities investigation, as any adverse findings could have further material negative impacts on SLQT's financials, operations, and market valuation.
• Re-evaluate risk exposure to SLQT, considering the potential for continued share price volatility and downside pressure stemming from the ongoing legal uncertainties and the company's demonstrated inability to meet revenue and earnings expectations.
• Assess potential contagion risk or heightened scrutiny for other entities named in the DOJ lawsuit, such as Humana (HUM), although the immediate sentiment and stock impact appear most concentrated on SelectQuote.